相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial
Nicholas Turner et al.
CANCER RESEARCH (2023)
Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers
Milana A. Bergamino et al.
CLINICAL CANCER RESEARCH (2022)
HCB-ONC001 ELPIS TRIAL: Omission of surgery and sentinel lymph node dissection in clinically low-risk HER2-positive breast cancer with high HER2 addiction and a complete response following standard anti-HER2-based neoadjuvant therapy
T. Pascual et al.
ANNALS OF ONCOLOGY (2022)
Clinicopathological and transcriptomic characterization of luminal HER2-enriched breast cancer
L. Hohmann et al.
ANNALS OF ONCOLOGY (2022)
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
Soohyeon Lee et al.
BREAST (2022)
Solti-1716. Targeting with pembrolizumab plus paclitaxel non-luminal by PAM50 hormone receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK4/6 inhibitor treatment (TATEN trial)
Eva Ciruelos et al.
CANCER RESEARCH (2022)
Solti-1905. Elacestrant in preoperative setting, a window of opportunity study (ELIPSE trial)
Maria Vidal et al.
CANCER RESEARCH (2022)
Genomic and transcriptomic analysis reveals known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet therapy (palbociclib plus everolimus plus exemestane) in a phase I/IIb study in hormone-receptor positive (HR+)/HER2-metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i)
Jorge Gomez Tejeda Zanudo et al.
CANCER RESEARCH (2022)
Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2-advanced breast cancer (ABC) across the MONALEESA (ML) studies
Aleix Prat et al.
CANCER RESEARCH (2022)
Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC)
Eva Ciruelos et al.
CANCER RESEARCH (2022)
Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2,-3, and-7 studies of ribociclib plus endocrine therapy in patients with HR+/HER2-advanced breast cancer
Lisa Carey et al.
CANCER RESEARCH (2022)
Prognostic value of intrinsic subtypes (IS) in hormone receptor-positive (HoR plus ) metastatic breast cancer (MBC): A systematic review and meta-analysis of prospective trials
Francesco Schettini et al.
CANCER RESEARCH (2022)
Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC)
Meritxell Bellet et al.
CANCER RESEARCH (2022)
Solti-1801. Analysis of the efficacy of CDK4/6 inhibitors in combination with hormonal treatment in luminal breast cancer in relation to the intrinsic subtype and markers of immunity (CDK-predict)
Pablo Tolosa et al.
CANCER RESEARCH (2022)
Serial genomic profiling reveals molecular mechanisms of breast cancer resistance to palbociclib
Zhengyan Kan et al.
CANCER RESEARCH (2022)
Gene expression profiles of breast cancer metastasis according to organ site
Fara Braso-Maristany et al.
MOLECULAR ONCOLOGY (2022)
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons
Paolo Tarantino et al.
CANCER DISCOVERY (2022)
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer
Paolo Tarantino et al.
JAMA ONCOLOGY (2022)
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
Milana A. Bergamino et al.
EBIOMEDICINE (2022)
A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes
Francesco Schettini et al.
NPJ BREAST CANCER (2022)
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
Joshua J. Gruber et al.
NATURE CANCER (2022)
Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
A. Marra et al.
ANNALS OF ONCOLOGY (2022)
HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC)
T. Pascual et al.
ANNALS OF ONCOLOGY (2022)
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1) a randomised, open-label, multicentre, phase 3 trial
Francois-Clement Bidard et al.
LANCET ONCOLOGY (2022)
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
Aleix Prat et al.
JAMA ONCOLOGY (2022)
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
Francesco Schettini et al.
FRONTIERS IN ONCOLOGY (2022)
Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer
Uzma S. Asghar et al.
JCO PRECISION ONCOLOGY (2022)
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A. Gennari et al.
ANNALS OF ONCOLOGY (2021)
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL
M. Martin et al.
ANNALS OF ONCOLOGY (2021)
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Francesco Schettini et al.
NPJ BREAST CANCER (2021)
CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data
O. Martinez-Saez et al.
ANNALS OF ONCOLOGY (2021)
Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression
Fabiana Luond et al.
BRITISH JOURNAL OF CANCER (2021)
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Aleix Prat et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
Tomas Pascual et al.
NPJ BREAST CANCER (2021)
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Philippe Aftimos et al.
CANCER DISCOVERY (2021)
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
Elisa Agostinetto et al.
CANCERS (2021)
Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer
Fara Braso-Maristany et al.
FRONTIERS IN ONCOLOGY (2021)
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2020)
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Aleix Prat et al.
LANCET ONCOLOGY (2020)
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Dennis J. Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Fara Braso-Maristany et al.
NATURE COMMUNICATIONS (2020)
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Paolo Tarantino et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer
Aleix Prat et al.
CLINICAL CANCER RESEARCH (2020)
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2020)
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J. K. Litton et al.
ANNALS OF ONCOLOGY (2020)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2
Aleix Prat et al.
ONCOLOGIST (2019)
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy
Adrienne G. Waks et al.
CLINICAL CANCER RESEARCH (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
S. -A. Im et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
244PImmune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial
G Griguolo et al.
ANNALS OF ONCOLOGY (2019)
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Yeon Hee Park et al.
LANCET ONCOLOGY (2019)
Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer
Juan Miguel Cejalvo et al.
CANCER TREATMENT REVIEWS (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
Ben O'Leary et al.
CANCER DISCOVERY (2018)
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
P. Cottu et al.
ANNALS OF ONCOLOGY (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Antonio Llombart-Cussac et al.
LANCET ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers
Delphine Hequet et al.
PLOS ONE (2017)
Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts
Arian Lundberg et al.
CLINICAL CANCER RESEARCH (2017)
PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients
Nicholas P. Tobin et al.
CLINICAL CANCER RESEARCH (2017)
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
T. Fujii et al.
ANNALS OF ONCOLOGY (2017)
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Juan M. Cejalvo et al.
CANCER RESEARCH (2017)
Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse
Claudette Falato et al.
MOLECULAR ONCOLOGY (2016)
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going
Francesco Schettini et al.
CANCER TREATMENT REVIEWS (2016)
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer
R. Wuerstlein et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
Celine Lefebvre et al.
PLOS MEDICINE (2016)
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib
Aleix Prat et al.
JAMA ONCOLOGY (2016)
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)
Minetta C. Liu et al.
NPJ BREAST CANCER (2016)
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
Brett Wallden et al.
BMC MEDICAL GENOMICS (2015)
Clinical implications of the intrinsic molecular subtypes of breast cancer
Aleix Prat et al.
BREAST (2015)
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer
Miguel Martin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast
Maria Vidal et al.
MOLECULAR ONCOLOGY (2015)
Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
Maggie C. U. Cheang et al.
ONCOLOGIST (2015)
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
N. P. Tobin et al.
ANNALS OF ONCOLOGY (2015)
PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients
Charlotte L. T. Jorgensen et al.
ACTA ONCOLOGICA (2014)
Androgen Receptor Expression Shows Distinctive Significance in ER Positive and Negative Breast Cancers
Julia Y. S. Tsang et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
Torsten Nielsen et al.
BMC CANCER (2014)
Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Aleix Prat et al.
CLINICAL CANCER RESEARCH (2014)
Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis
Francisco E. Vera-Badillo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
Aleix Prat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More?
William F. Anderson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Dawn R. Cochrane et al.
BREAST CANCER RESEARCH (2014)
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
Miguel Martin et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer
Aleix Prat et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
APOBEC3B mutagenesis in cancer
Kawai J. Kuong et al.
NATURE GENETICS (2013)
Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
Aleix Prat et al.
ONCOLOGIST (2013)
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
A. Prat et al.
ANNALS OF ONCOLOGY (2012)
PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
Roy R. L. Bastien et al.
BMC MEDICAL GENOMICS (2012)
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
T. Hatschek et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
Linda Sofie Lindstrom et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Gemcitabine Plus Docetaxel Versus Docetaxel in Patients With Predominantly Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Randomized, Phase III Study by the Danish Breast Cancer Cooperative Group
Dorte L. Nielsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
Laura C. Collins et al.
MODERN PATHOLOGY (2011)
Deconstructing the molecular portraits of breast cancer
Aleix Prat et al.
MOLECULAR ONCOLOGY (2011)
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
Torsten O. Nielsen et al.
CLINICAL CANCER RESEARCH (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer
Amelia A. Peters et al.
CANCER RESEARCH (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Epidemiology of basal-like breast cancer
Robert C. Millikan et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Genes that mediate breast cancer metastasis to lung
AJ Minn et al.
NATURE (2005)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A multigenic program mediating breast cancer metastasis to bone
YB Kang et al.
CANCER CELL (2003)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
分享论文
